Overview
Spotlight Pathology, a spinout from the University of Manchester, has secured £1.4 million to accelerate the rollout of its AI-powered cancer diagnostics product, specifically for diagnosing blood cancer. The funding round was co-led by Liverpool City Region Seed Fund and UKI2S, with support from Deepbridge, Lyva Labs, EHE Ventures, and River Capital. The company aims to transition from tech development to clinical use, with the first deployments expected in NHS sites later this year.
Products
Loading...
Recent Deals
Investors: Liverpool City Region Seed Fund, UKI2S, Deepbridge, Lyva Labs, EHE Ventures, River Capital
Spotlight Pathology, a spinout from the University of Manchester, has secured £1.4 million to accelerate the rollout of its AI-powered cancer diagnostics product, specifically for diagnosing blood cancer. The funding round was co-led by Liverpool City Region Seed Fund and UKI2S, with support from Deepbridge, Lyva Labs, EHE Ventures, and River Capital. The company aims to transition from tech development to clinical use, with the first deployments expected in NHS sites later this year.
Investors: UK Innovation and Science Seed Fund, Future Planet Capital
Spotlight Pathology has raised £1.4 million in seed funding to enhance its AI software for analyzing digital pathology images, aiding clinicians in the faster and more consistent diagnosis of blood cancers. The technology addresses the challenges of rising demand and staff shortages in UK pathology departments. The funding will support regulatory approvals and early clinical trials as the company aims for wider clinical use. Key investors include the UK Innovation and Science Seed Fund, managed by Future Planet Capital.